Adverse events from new targeted therapies, BRAF and MEK inhibitors, in a patient with metastatic melanoma
Keywords:BRAF inhibitor, MEK inhibitor, dabrafenib, trametinib, naranjo, metastatic melanoma, targeted therapy
Authors retain copyright, simultaneously licensing their works under a Creative Commons Attribution 4.0 International License (CC BY 4.0). That license allows others to share and adapt the work so long as they provide reasonable attribution. This license applies to the submitted version of the work (preprint), the accepted version of the work (postprint), and the final published version.
Ideal attribution for a work published in this journal consists of the work’s title, the title of the journal, the name(s) of the author(s), the DOI (digital object identifier), and a link to the CC BY 4.0 license deed. The journal encourages those relying on the CC BY 4.0 license to consult the Best Practices for Attribution on the Creative Commons wiki.
As they retain copyright, authors are entitled to distribute any version of the article and to grant other licenses to use the work, subject to the CC BY 4.0 license. The journal encourages authors to include the ideal attribution described above when they distribute their works after acceptance by the journal.
Authors are encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and after publication, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see SPARC's "Open Access" article).